Positive Topline Results of Phase III Trial

Summary by AI BETAClose X

HUTCHMED announced positive topline results from the Phase III ESLIM-02 trial of sovleplenib for warm antibody autoimmune hemolytic anemia (wAIHA) in China, meeting its primary endpoint of durable hemoglobin response rate. The trial demonstrated rapid and durable responses in wAIHA patients who had relapsed or were refractory to prior treatments, with previous Phase II data showing a 66.7% overall response rate over 24 weeks. HUTCHMED plans to submit a New Drug Application to the China National Medical Products Administration in the first half of 2026, and also plans a resubmission for sovleplenib for second-line immune thrombocytopenia in the same timeframe.

Disclaimer*

UK 100

Latest directors dealings